Quantcast

Latest Organofluorides Stories

2014-09-07 08:20:28

MarketOptimizer.org adds new report "Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. DALLAS, Sept. 7, 2014 /PRNewswire-iReach/ -- New PharmaPoint Drug Evaluation report, "Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of...

2014-09-07 08:20:19

DALLAS, September 7, 2014 /PRNewswire/ -- MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. The Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 report estimates that the total market size for the 7MM in...

2014-09-05 23:00:54

Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone. Data Presented at International Liver Cancer Association Conference. MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with...

2014-09-04 08:29:50

Pharmacokinetics, Safety and Tolerability of NVR-1221 Support Advancement to Phase 1b Clinical Studies in Patients with Chronic HBV Infection DOYLESTOWN, Pa., Sept. 4, 2014 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221. The results for the Phase 1a clinical study...

2014-09-03 08:33:52

Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market SAN ANTONIO, Sept. 3, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the World Health Organization's (WHO) International Nonproprietary Name (INN) group has recommended the generic name "mipsagargin" (mip sa gar' jin) for its lead drug candidate, also...

2014-09-02 16:25:30

AUSTIN, Texas, Sept. 2, 2014 /PRNewswire/ -- XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix(TM). Xilonix, a True Human(TM) monoclonal antibody therapy, is being evaluated in advanced colorectal cancer patients where disease is further complicated with cachexia. The primary endpoint of the study is overall survival, comparing survival in Xilonix treated patients to a control population provided...

2014-09-01 23:01:31

The Firm is evaluating potential Lipitor lawsuits on behalf of individuals who allegedly developed Lipitor diabetes injuries after taking the cholesterol-lowering statin drug. New York, NY (PRWEB) September 01, 2014 More than 200 Lipitor lawsuit (http://www.thelipitorlawsuit.com/) filings have been added to a federal litigation that continues to progress in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. A federal Case List published on August 15th...

2014-08-31 04:21:07

Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS, Aug. 31, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.(...

2014-08-31 04:20:55

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y., Aug. 31, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia....

2014-08-29 16:21:39

DUBLIN, Ireland, August 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/ljjdcg/global) has announced the addition of the "Global Trifluoroacetic Acid Industry Report 2014" [http://www.researchandmarkets.com/research/ljjdcg/global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Global Trifluoroacetic Acid Industry Report 2014 is a professional and in-depth study on the current state of...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.